“…A role for the OX1R in mediating intake of palatable food is supported by the findings that systemic injection of the OX1R antagonist, SB-334867, reduces operant responding for both sucrose and saccharin pellets, in a minimal work paradigm with a fixed ratio 1 schedule (Cason & Aston-Jones, 2013a, 2013b, 2014). This antagonist also suppresses binge-like intake of sucrose, saccharin, and fructose solutions under an intermittent-access home cage drinking paradigm (Alcaraz-Iborra, Carvajal, Lerma-Cabrera, Valor, & Cubero, 2014; Rorabaugh, Stratford, & Zahniser, 2014) and reduces intake of a high-fat diet under both ad libitum and limited-access feeding paradigms (Choi, Davis, Fitzgerald, & Benoit, 2010; Valdivia, Patrone, Reynaldo, & Perello, 2014; White et al, 2005). Other OX1R antagonists similarly reduce intake of sweet-fat foods whether under ad libitum or intermittent-access feeding paradigms (Piccoli et al, 2012; Steiner, Sciarretta, Pasquali, & Jenck, 2013).…”